MLD Foundation

New Year’s Reflections … and Highlights from December Meeting in Boston

Happy New Year!  As we head out of the holiday season and into a new year, it is a time that we reflect on life, cherish family, and count our blessings for all that we hold close to our hearts. Holiday music has been playing everywhere you go for the past month; while I enjoy

New Year’s Reflections … and Highlights from December Meeting in Boston Read More »

Mld Family Conference™ – Register Now!

Registration for our 2105 MLD Family Conference in Newark Delaware is underway and closes in just a couple of weeks.  If you are a MLD Family we’re anxious to have you register. Many of your MLD Family will be there to meet, share, and socialize with. Please bring your MLD loved one with you – we not only want

Mld Family Conference™ – Register Now! Read More »

Centers of Excellence for Leukodystrophies and Lysosomal Disease

Earlier last month we had the opportunity to see several presentations about the Leukodystrophy Center of Excellence (CoE) at Children’s Hospital of Philadelphia (CHOP), which opened today, May 1st. The mission of the [CHOP Leukodystrophy CoE] center is “to deliver cutting-edge, integrated, multidisciplinary clinical care, diagnostic evaluation, and therapeutics to infants, children and youth with inherited white matter disease.”

Centers of Excellence for Leukodystrophies and Lysosomal Disease Read More »

openNHS Manifesto – Meeting Report

A meeting of researchers, clinicians, industry and academia was convened by the MLD Foundation on June 24th in Washington, DC to discuss the openNHS Manifesto we wrote about in this blog post. Since a NHS is not a therapy, NHS participants have historically be giving time, energy, and effort, not to mention exposing their MLD loved ones to occasional invasive

openNHS Manifesto – Meeting Report Read More »

ERT Phase I/II Clinical Trial Recruiting Completed

The Enzyme Replacement Therapy HGT-1110 Phase I/II clinical trial has been fully recruited.  Patients are participating from three continents; Europe, South America, and Australia. The primary purpose of a Phase I/II clinical trial is to study safety and to establish a target dosage for further study. The trial lasts 40-weeks so the last patient should complete their

ERT Phase I/II Clinical Trial Recruiting Completed Read More »

Report from FDA PFFD IEM meeting

Great Patient Focused Drug Development (PFDD) meeting at the FDA Tuesday discussing patients perspective on the neurological inborn errors of metabolism (IEM). Dean Suhr, president of the MLD Foundation, spoke on the second panel of the day and was able to both share and stir the pot a bit with regard to some of the patient perspectives on

Report from FDA PFFD IEM meeting Read More »